NeoControl® has been cleared by the FDA for the treatment of urinary incontinence in women; however, research is continuing to further refine the role of ExMI™ technology as a conservative incontinence therapy.

Indications are strong that ExMI technology has broad clinical applications throughout the pelvic region, and studies are planned to investigate potential applications for male incontinence, prostate therapy, male and female sexual dysfunction, intersticial cystitis (IC), pelvic pain and fecal incontinence.